

1 Folding LacZ in the periplasm of *Escherichia coli*

2

3

4 Robert S. Dwyer,<sup>a</sup> Juliana C. Malinverni,<sup>a</sup> Dana Boyd,<sup>b</sup> Jon Beckwith,<sup>b</sup> and Thomas J.

5 Silhavy<sup>a#</sup>

6

7 Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA<sup>a</sup>;

8 Department of Microbiology and Immunology, Harvard Medical School, Boston,

9 Massachusetts, USA<sup>b</sup>

10

11 Running Head: Folding LacZ in the periplasm of *Escherichia coli*

12

13 #Address correspondence to [tsilhavy@princeton.edu](mailto:tsilhavy@princeton.edu).

14

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35ABSTRACT

Targeted, translational LacZ fusions provided the initial support for the signal sequence hypothesis in prokaryotes and allowed for selection of the mutations that identified the Sec translocon. Many of these selections relied on the fact that expression of targeted, translational *lacZ* fusions like *malE-lacZ* and *lamB-lacZ42-1* causes lethal toxicity as folded LacZ jams the translocation pore. But there is another class of targeted LacZ fusions that do not jam the translocon. These targeted, non-jamming fusions also show toxic phenotypes that may be useful for selecting mutations in genes involved in post-translocational protein folding and targeting; however, they have not been investigated to the same extent as their jamming counterparts. In fact it is still unclear whether LacZ can be fully translocated in these fusions. It may be that they simply partition into the inner membrane where they can no longer participate in folding or assembly. In the present study we systematically characterize the non-jamming fusions and determine their ultimate localization. We report that LacZ can be fully translocated into the periplasm where it is toxic. We show that this toxicity is likely due to LacZ misfolding and that in the absence of the periplasmic disulfide bond catalyst DsbA, LacZ folds in the periplasm. Using the novel phenotype of periplasmic  $\beta$ -galactosidase activity, we show that the periplasmic chaperone FkpA contributes to LacZ folding in this non-native compartment. We propose that targeted, non-jamming LacZ fusions may be used to further study folding and targeting in the periplasm of *Escherichia coli*.

## INTRODUCTION

36

37 Translational LacZ fusions have been used to study protein targeting in  
38 *Escherichia coli* for over thirty-five years. The hybrid proteins produced by such fusions  
39 comprise an N-terminal targeting sequence fused to a C-terminal, often functional  
40 fragment of LacZ. The targeting sequence may consist of an outer membrane protein  
41 (OMP) like LamB, a soluble periplasmic protein, or an integral inner membrane (IM)  
42 protein like MalF. Each of these hybrid proteins has in common an N-terminal signal  
43 sequence, which targets it to the Sec translocon at the inner membrane (IM).

44

The first *lamB-lacZ* fusions were described in 1977, and a subset of these were  
45 found to confer sensitivity to the inducer maltose (1). Induction of targeted hybrid  
46 proteins like LamB-LacZ<sub>42-1</sub> causes massive accumulation of the precursor forms of  
47 envelope proteins in the cytoplasm (2). It seems the hybrid proteins jam the secretion  
48 machinery, causing a global reduction in translocation efficiency. Jamming in turn leads  
49 to proteolytic degradation of the essential components of the Sec translocase and  
50 eventually to cell death (3). Screens for mutations that relieve lethal jamming without  
51 preventing synthesis of the LamB-LacZ<sub>42-1</sub> hybrid protein (Mal<sup>R</sup> Lac<sup>+</sup>) return mutations  
52 in *lamB* that prevent fusion targeting by altering the signal sequence (4). The  $\Delta 60$ *lamB-*  
53 *lacZ* fusion, which contains a *lamB* signal sequence deletion, was identified in this way  
54 (5). Such mutants provided important support for the signal sequence hypothesis in  
55 bacteria. Together, findings with the *lamB-* and *malE-lacZ* (2) fusions made possible the  
56 selections and screens that identified the *sec* and *pri* alleles, which defined the  
57 components of the Sec translocon during the 1980s (6–9).

58           The role of LacZ in hybrid jamming was determined in studies with two  
59 derivatives of *lamB-lacZ42-1*, which show that envelope protein precursors do not  
60 accumulate if LacZ folding is prevented prior to translocation. The first fusion, *lamB-*  
61 *lacZX90*, contains an *ochre* mutation that prevents folding by truncating the last ten  
62 amino acids of LacZ (10, 11). The second fusion, *H\*lamB-lacZ*, prevents folding by  
63 altering the targeting pathway of the hybrid protein. *H\** denotes a mutant *lamB* signal  
64 sequence with increased hydrophobicity, which reroutes the fusion from the usual post-  
65 translational, SecB-dependent targeting pathway to the co-translational, signal  
66 recognition particle (SRP) pathway (12). Because translation and translocation are  
67 coupled in the SRP pathway, LacZ cannot fold prior to translocation (12). Both the  
68 *lacZX90* and *H\*lamB* mutations relieve the lethal jamming caused by LamB-LacZ42-1,  
69 and, because neither fusion jams the secretion machinery, they must allow LacZ  
70 sequences to exit the Sec translocon (11, 12).

71           Despite the fact that the *X90* and *H\** mutations relieve jamming, induction of  
72 either fusion is lethal (11, 12). The toxicity conferred by these fusions is manifest in the  
73 periplasm as evidenced by the fact that overproduction of the periplasmic protease DegP  
74 relieves this toxicity (11, 12). In marked contrast, the lethal jamming caused by the  
75 LamB-LacZ42-1 hybrid protein is not relieved by overproduction of DegP (11, 12).  
76 Periplasmic toxicity is likely due to the oxidizing nature of the periplasm, which causes  
77 LacZ to misfold and aggregate (11, 13, 14). The LamB-LacZX90 hybrid protein forms  
78 periplasmic disulfide-bonded aggregates that can be disrupted by removing the disulfide  
79 bond catalyst DsbA, although this does not relieve maltose sensitivity (see below). LacZ

80 is also known to misfold in strains expressing the *H\*lamB-lacZ* fusion, because it does  
81 not confer  $\beta$ -galactosidase activity (12).

82         The same is true of another co-translationally targeted *lacZ* fusion, *malF-lacZ102*,  
83 which encodes a hybrid protein comprising a folding-competent LacZ moiety fused to the  
84 third transmembrane segment of the integral IM protein MalF (14). MalF topology  
85 suggests that LacZ is exposed to the periplasm when this hybrid protein partitions into the  
86 membrane. Interestingly, selection for  $\beta$ -galactosidase activity in strains expressing the  
87 *malF-lacZ102* fusion returns extragenic (unlinked) mutations that inactivate the *dsbA*  
88 gene (15). Because LacZ is only known to fold in the cytoplasm *in vivo*, restoration of  $\beta$ -  
89 galactosidase activity in strains expressing *malF-lacZ102* fusion has been attributed to  
90 the re-localization of LacZ to the cytoplasm, although it has also been suggested the LacZ  
91 may be folding in the periplasm (16). According to the cytoplasmic model, the LacZ  
92 moiety in MalF-LacZ102 partitions into the membrane along with MalF, adopting an  
93 inactive, transmembrane structure that is stabilized by intra-LacZ disulfide bonds at the  
94 periplasmic face of the IM. In the absence of DsbA, the exergonic folding reaction pulls  
95 LacZ through the membrane into the cytoplasm where it can become active (15).

96         Perhaps LacZ contains cryptic stop-transfer sequences that prevent complete  
97 translocation of any hybrid protein containing LacZ. Indeed, it is not clear whether the  
98 LamB-LacZX90 or *H\*LamB-LacZ* hybrid proteins are fully translocated into the  
99 periplasm either. Fractionation of these hybrid proteins has proven difficult, because  
100 their misfolding promotes aggregation. The best evidence for full translocation is the fact  
101 that DegP overexpression relieves inducer sensitivity in strains expressing these targeted,  
102 non-jamming fusions (11, 12); however, this result does not preclude a model whereby

103 hybrid protein partitions into the IM and confers toxicity through exposed periplasmic  
104 domains. Neither the toxicity conferred by high-level production of the MalF-LacZ102  
105 hybrid protein nor the effects of DegP overproduction in these fusion strains has been  
106 systematically examined.

107         If the  $\beta$ -galactosidase activity exhibited by the MalF-LacZ102 hybrid protein in  
108 the absence of DsbA reflects periplasmic localization of LacZ activity, then this strain  
109 should grow on lactose in the absence of the lactose permease, LacY. However, fusion  
110 toxicity complicates this simple genetic test because low levels of cell lysis caused by  
111 fusion toxicity can support growth by releasing soluble  $\beta$ -galactosidase from the  
112 cytoplasm (1). On the other hand biochemical experiments demonstrating full  
113 translocation of the  $\beta$ -galactosidase portion of the MalF-LacZ102 hybrid protein are  
114 complicated by the fact that the hybrid protein is membrane bound and thus insoluble.

115         In the present study we seek to determine whether LacZ can be fully translocated  
116 into the periplasm, and, if so, whether it can fold and what periplasmic factors might be  
117 involved. We suggest that the *H\*lamB-lacZ* and *malF-lacZ102* fusions provide a useful  
118 tool to study protein quality control pathways in the periplasm that help maximize the  
119 production of heterologous proteins that require secretion and oxidation in *E. coli*.

120

121

MATERIALS AND METHODS122 **Strains and plasmids**

123 Strains and plasmids used in this study are listed in Table 1. All strains are  
124 derivatives of NR754, an Ara<sup>+</sup> revertant of *Escherichia coli* MC4100. Marked alleles  
125  $\Delta dsbA::Kan^R$ ,  $\Delta fkpA::Cm^R$ , and *lacY::Tn9* were moved by transduction with  
126 bacteriophage P1 (17). CWB299 is merodiploid, containing both the *H\*lamB-lacZ*  
127 fusion and a copy of the *lamB* gene with the *H\** signal sequence (Fig. 1A). We found  
128 that the extra copy of the *Pmal* promoter (a divergent promoter) led to a significant  
129 decrease in levels of hybrid protein. To facilitate comparison with the other fusion  
130 strains, we created a haploid version of *H\*lamB-lacZ* (JCM944) by recombineering (18)  
131 (Fig. 1F). To generate the *H\*lamB-lacZ* deletion series, a fragment of the fusion was  
132 cloned into pBR322 (pRSD02), and regions of mature *lamB* sequence were removed  
133 using a plasmid-based PCR method (19). Fusions were then amplified from the plasmid  
134 by PCR and recombineered into JCM932 as described for JCM944.

135

136 **Media and growth conditions**

137 All fusion strains were cultured overnight at 37°C with aeration in minimal M63  
138 media supplemented with 1% glucose (w/v) to repress expression of the fusion and 0.4%  
139 LB (v/v) unless otherwise noted (17). All subsequent experiments were carried out at  
140 37°C with aeration unless noted otherwise. Chloramphenicol (20 µg/ml), Kanamycin (25  
141 µg/ml), and Ampicillin (125 µg/ml) (Sigma) were included in overnight cultures and  
142 plates as necessary to select for plasmid retention or recombination.

143

144 **Maltose disc diffusion assays**

145           Overnight cultures were resuspended in M63 minimal media. 100  $\mu$ l aliquots of  
146 resuspended cells were then mixed with three milliliters molten M63 top agar and spread  
147 evenly on a plate containing M63 bottom agar. Bottom and top agar were supplemented  
148 with 0.2% glycerol and 0.4% LB and antibiotics as needed. Filter discs infused with 15  
149  $\mu$ l of 20% maltose (Sigma) were placed in the center of the plates once the top agar  
150 solidified. Plates were incubated overnight, and the diameters of zones of inhibition were  
151 measured. Measurements exclude the diameter of the filter disc. Representative  
152 experiments are shown.

153

154  **$\beta$ -galactosidase assays**

155           Overnight cultures were resuspended and subcultured 1:50 into LB. Cultures  
156 were grown two to three hours to mid-log phase. 1 ml aliquots of culture were pelleted  
157 and permeabilized using chloroform and SDS.  $\beta$ -galactosidase assays were performed in  
158 triplicate according to Miller (20). Spectrophotometric readings were taken at one-  
159 minute intervals over the course of a 15-minute ONPG hydrolysis reaction, and arbitrary  
160 units were calculated from measurements of  $V_{max}$  after normalization to cell culture  
161 density as determined by OD<sub>600</sub> readings.

162

163 **Growth rate determination**

164           Overnight cultures were washed twice in minimal M63 media and subcultured  
165 1:50 in 5 ml M63 minimal media containing either 1% glycerol or 1% lactose. Media  
166 was not supplemented with LB. Growth was measured by OD<sub>600</sub> reading every hour over



167 an eight hour time period. Growth rates were determined during exponential growth  
168 using three data points.

169

### 170 **Spheroplasting**

171 Overnight cultures were resuspended and subcultured 1:50 into 50 ml liquid LB  
172 cultures. Cultures were grown two to three hours until reaching mid-log phase. Cultures  
173 were then split and subject to either spheroplasting or lysis in SDS-PAGE sample buffer  
174 (21). After pelleting spheroplasts, supernatants containing soluble periplasmic  
175 components were filtered and subjected to  $\beta$ -galactosidase assay and SDS-PAGE and  
176 Western blot alongside whole cell lysates.

177

### 178 **Western blotting**

179 Samples resuspended in SDS-PAGE sample buffer were boiled 10 min and  
180 subjected to electrophoresis on a 12% polyacrylamide gel. Immunoblotting was  
181 performed with MBP (1:30,000 dilution) and CpxR (1:10,000 dilution) antisera, and  
182 detection was performed with ECL antibody detection kit (Amersham), and Hyblot CL  
183 film (Denville Scientific).

184

185

RESULTS186 **Targeted, non-jamming fusions confer periplasmic toxicity**

187 To determine whether LacZ can be fully translocated into the periplasm, we first  
188 set out to see if the non-jamming fusions confer similar phenotypes. We reasoned that if  
189 the *malF-lacZ102* fusion also confers maltose sensitivity, some significant portion of  
190 LacZ might be exposed to the periplasm in this strain. Using a disc diffusion assay to  
191 measure maltose sensitivity, we found that the *malF-lacZ102* fusion does indeed confer  
192 maltose sensitivity (Table 2). Because *malF-lacZ102* is plasmid-borne, the size of the  
193 zone of clearing cannot be compared directly to those of the other fusion strains, except  
194 to say that strains harboring this fusion are certainly Mal<sup>S</sup>.

195 Previously it was shown that overexpression of the periplasmic protease DegP is  
196 sufficient to relieve the Mal<sup>S</sup> phenotype conferred by the *H\*lamB-lacZ* and *lamB-*  
197 *lacZX90* fusions. To ensure that the maltose sensitivity conferred by the *malF-lacZ102*  
198 fusion results from periplasmic toxicity rather than some deleterious effect in the IM, we  
199 determined the effect of DegP overexpression on the fusion strain. Using maltose disc  
200 diffusion assays, we found that DegP overexpression caused strains expressing the *malF-*  
201 *lacZ102* fusion to become Mal<sup>R</sup> (Table 2). Note that DegP does not relieve the Mal<sup>S</sup>  
202 phenotype of the jamming *lamB-lacZ42-1* fusion, which does not reach the periplasm.  
203 The fact that all three non-jamming fusions confer a Mal<sup>S</sup> phenotype that can be relieved  
204 by DegP overexpression suggests that despite differences in targeting sequences and  
205 translocation pathways, the hybrid protein is exposed to the periplasm in all three fusions.  
206

207 **Toxicity of targeted, non-jamming fusions is caused by misfolded LacZ in the**  
208 **periplasm**

209           The fact that the *malF-lacZ102* fusion confers periplasmic toxicity suggests that  
210 the toxicity in all strains may be unrelated to targeting steps downstream of translocation.  
211 MalF should not cause the MalF-LacZ102 hybrid protein to titrate periplasmic  
212 chaperones or to interfere with the essential OMP assembly machinery because (1) as an  
213 IM protein it should not contain any signal for downstream interactions, and (2) it should  
214 tether the hybrid protein to the IM where it cannot interact with OM proteins. To test that  
215 the toxicity conferred by the *H\*lamB-lacZ* fusion is also a result of localizing LacZ to the  
216 periplasm, a series of deletion constructs were made, removing *lamB* sequence from the  
217 fusion while leaving the signal sequence intact. These fusions should still be targeted to  
218 the translocon, but any downstream targeting signals contained in the *lamB* fragment  
219 should be removed by successive deletions. We found no discernible change in the Mal<sup>S</sup>  
220 phenotype of any of the deletion constructs, even when only five amino acids of mature  
221 *lamB* were included in the fusion (Table 3). This result supports the conclusion that  
222 periplasmic LacZ is the sole source of toxicity in these targeted, non-jamming fusions.

223           Since the LamB-LacZX90 hybrid protein is known to form disulfide-bonded  
224 aggregates in the periplasm, we wondered if disulfide bond formation may contribute to  
225 the periplasmic toxicity of LacZ. Indeed, LacZ contains a total of 16 cystein residues,  
226 any of which could participate in aberrant intra- or inter-molecular disulfide bonds. To  
227 test this hypothesis, we deleted the gene encoding the periplasmic disulfide bond catalyst  
228 DsbA. We found by disc diffusion assay that the *dsbA::Kan<sup>R</sup>* insertion-deletion partially  
229 relieves the Mal<sup>S</sup> phenotype conferred by the *H\* lamB-lacZ* and *malF-lacZ102* fusions;

230 however, it does not relieve the Mal<sup>S</sup> phenotype of cells expressing the *lamB-lacZX90*  
231 fusion (Table 2). The *lamB-lacZX90* result is consistent with a previous report showing  
232 *dsbA* deletion does not affect maltose sensitivity in this strain (11). Together, these  
233 findings suggested that LacZ must be folding-competent in order for *dsbA* disruption to  
234 relieve maltose sensitivity. We hypothesized that in the absence of DsbA, LacZ can fold  
235 in the periplasm, which reduces its toxicity in turn.

236

### 237 **In the absence of DsbA, LacZ folds in the periplasm**

238 To determine whether LacZ is folding in the absence of DsbA,  $\beta$ -galactosidase  
239 assays were performed on whole-cell lysates derived from the various fusion strains. As  
240 expected the  $\Delta 60\textit{lamB-lacZ}$  and *lamB-lacZ42-1* fusions, which lead to retention of LacZ  
241 in the cytoplasm, exhibited  $\beta$ -galactosidase activity whether or not DsbA was present  
242 (Fig. 2). In the presence of DsbA, none of the targeted, non-jamming fusions conferred  
243  $\beta$ -galactosidase activity; however, strains expressing the *H\* lamB-lacZ* and *malF-*  
244 *lacZ102* fusions showed significant  $\beta$ -galactosidase activity upon *dsbA* disruption (Fig.  
245 2). Coupled with the reduction in maltose sensitivity, this increase in  $\beta$ -galactosidase  
246 activity in targeted, non-jamming fusions supports the hypothesis that misfolded LacZ is  
247 toxic in the periplasm.

248 We took two complementary approaches to determine whether the  $\beta$ -  
249 galactosidase activity exhibited by strains expressing the *H\*lamB-lacZ* or *malF-lacZ102*  
250 fusions is localized to the periplasm. In the first approach, we took advantage of the fact  
251 that otherwise wild-type strains require the inner membrane lactose permease LacY to  
252 grow in minimal lactose media. In the absence of LacY, lactose cannot reach the

253 cytoplasm where LacZ activity normally resides. We reasoned that if LacZ were instead  
254 localized and active in the periplasm, it could cleave periplasmic lactose into galactose  
255 and glucose, which could be imported by other means, thereby conferring growth in  
256 minimal lactose even in the absence of LacY. To this end we tested the ability of strains  
257 expressing the *H\*lamB-lacZ* and *malF-lacZ102* fusions to grow in minimal lactose in  
258 three genetic backgrounds: *lacY<sup>+</sup> dsbA<sup>+</sup>*, *lacY::Tn9 dsbA<sup>+</sup>*, and *lacY::Tn9 dsbA::Kan<sup>R</sup>*.  
259 The  $\Delta 60lamB-lacZ$  fusion was used as a control exhibiting cytoplasmic  $\beta$ -galactosidase  
260 activity. As expected, strains expressing the  $\Delta 60lamB-lacZ$  fusion could only grow in the  
261 presence of LacY (Fig. 3A). Like  $\Delta 60lamB-lacZ$ , neither the *H\*lamB-lacZ* nor the *malF-*  
262 *lacZ102* fusions conferred a Lac<sup>+</sup> phenotype in a *lacY::Tn9 dsbA<sup>+</sup>* background; however,  
263 these strains became Lac<sup>+</sup> in the absence of DsbA (Fig. 3A)—the same condition in  
264 which they exhibit  $\beta$ -galactosidase activity. This evidence supports the hypothesis that  
265 LacZ can fold in the periplasm in the absence of DsbA. We note that growth in minimal  
266 lactose due to cell lysis is not consistent with these findings. If lysis were occurring, we  
267 would expect it to be higher in the *dsbA<sup>+</sup>* background, since the *dsbA::Kan<sup>R</sup>* allele  
268 relieves maltose sensitivity. Yet significant growth is only observed in the low-lysis  
269 condition. We conclude that the hydrolysis of lactose in the media by extracellular LacZ  
270 cannot explain the observed growth.

271 In the second approach, we determined whether  $\beta$ -galactosidase activity could be  
272 released along with other soluble periplasmic proteins during spheroplast formation.  
273 Because the MalF moiety tethers the MalF-LacZ102 hybrid protein to the IM, only the  
274 *H\*lamB-lacZ* fusion was used in this experiment. As expected, we found that cells  
275 expressing the  $\Delta 60lamB-lacZ$  fusion released less than 1% of whole-cell  $\beta$ -galactosidase

276 activity upon spheroplast formation (Fig. 3B). Conversely, cells expressing the *H\* lamB-*  
277 *lacZ* fusion released 52% of whole cell  $\beta$ -galactosidase activity upon spheroplast  
278 formation (Fig 3B). To ensure that release of  $\beta$ -galactosidase activity into the soluble  
279 fraction was not due to cell lysis, we attempted to detect cytoplasmic protein in  
280 spheroplast supernatants by western blotting. While we identified the cytoplasmic  
281 protein CpxR in whole-cell samples, it was absent from spheroplast supernatants,  
282 indicating that the IM was still intact and cytoplasmic proteins were not released by  
283 spheroplasting (Fig. 3C). Why roughly half of whole-cell  $\beta$ -galactosidase activity is  
284 retained in spheroplasts is unclear, although other studies have reported partial release of  
285 periplasmic proteins upon spheroplast formation (22). It is possible that a fraction of the  
286 hybrid protein is tightly associated with the IM or that translocation efficiency is reduced  
287 in the absence of DsbA. In any case, it is clear that in the absence of DsbA strains  
288 expressing the *H\*lamB-lacZ* fusion harbor folded, active LacZ in the periplasm.

289

#### 290 **FkpA contributes to LacZ folding**

291 We thought it likely that some periplasmic factor must be assisting LacZ folding.  
292 Because previous studies have implicated the periplasmic chaperones *skp* and *fkpA* in the  
293 folding of heterologous proteins (23–29), we chose to see what effect disruption of these  
294 genes might have on the  $\beta$ -galactosidase activity of a strain expressing the *malF-lacZ102*  
295 fusion in the absence of DsbA. While disruption of *skp* did not decrease  $\beta$ -galactosidase  
296 activity, we found that disruption of *fkpA* reduced it by a factor of 2.6 (Fig. 4). This  
297 result firmly supports the conclusion that the LacZ moiety in non-jamming targeted  
298 fusions is fully translocated into the periplasm where it can fold in the absence of DsbA.

299

300 DISCUSSION

301 Three lines of evidence support the conclusion that LacZ is fully translocated into  
302 the periplasm in targeted, non-jamming fusions. These three lines of evidence  
303 correspond to three periplasmic proteins, each of which alters the phenotypes conferred  
304 by the targeted, non-jamming fusions. First we showed that *malF-lacZ102* confers  
305 maltose sensitivity like the *H\* lamB-lacZ* and *lamB-lacZX90* fusions, and that the  
306 periplasmic chaperone/protease DegP can relieve this sensitivity. As DegP is itself  
307 localized to the periplasm and is a key component of the Cpx and  $\sigma^E$  stress responses in  
308 this compartment (30–32), we conclude that in all cases the toxicity conferred by  
309 targeted, non-jamming fusions is periplasmic and that LacZ is most likely fully  
310 translocated by extension.

311 The second line of evidence supporting full translocation concerns the periplasmic  
312 disulfide bond catalyst DsbA, which we found promotes the misfolding and toxicity of  
313 the *H\* LamB-LacZ* and *MalF-LacZ102* hybrid proteins. In the absence of DsbA, the  
314 LacZ moiety in these proteins can fold and become active in the periplasm, reducing its  
315 toxicity. Of course disruption of *dsbA* has no phenotypic effect on the *lamB-lacZX90*  
316 fusion, because the *X90* mutation prevents LacZ from folding in any compartment. This  
317 led us to conclude that it is misfolded LacZ in particular that is toxic in the periplasm.  
318 This hypothesis was confirmed when we found that a derivative of the *H\* lamB-lacZ*  
319 fusion encoding only the signal sequence and first five amino acids of LamB fused to  
320 LacZ was just as toxic as the full-length fusion. Interestingly, it has been reported that  
321 the signal sequence alone may not be sufficient for targeting and that more than 27 amino  
322 acids of mature LamB are needed in addition to the signal sequence to promote SecB-

323 dependent export of the LamB-LacZ hybrid protein (33, 34). It has also been suggested  
324 that the signal sequence may not play a role in targeting proteins to the Sec translocon *per*  
325 *se* (35). Our findings suggest that a signal sequence is both necessary and sufficient for  
326 targeting via the SRP pathway.

327         We believe the H\* signal sequence may present an ideal method for targeting  
328 exogenous proteins for folding in the oxidizing environment of the *E. coli* periplasm.  
329 While SecB-dependent targeting sequences like those derived from MBP are sufficient to  
330 target hybrid protein to the translocon, they risk lethal jamming. The H\* signal sequence  
331 avoids jamming by directing hybrid protein to the co-translational SRP pathway, which  
332 should allow for greater induction and higher yield of exogenous proteins. Also, the fact  
333 that the signal sequence alone seems to be sufficient for targeting means that little if any  
334 targeting sequence need remain after signal sequence cleavage.

335         The third line of evidence supporting full-translocation concerns the effect of  
336 FkpA on LacZ folding. FkpA is one of four known peptidyl-prolyl *cis-trans* isomerases  
337 in the periplasm (36). It functions as a chaperone *in vivo*, promoting assembly of OMPs.  
338 FkpA function overlaps at least in part with Skp function, and both seem to be involved  
339 in assembly of the essential OMP LptD (37), which is in turn responsible for inserting  
340 lipopolysaccharide (LPS) into the OM of Gram-negative bacteria like *E. coli* (38, 39). In  
341 the present study we found that disruption of *fkpA* leads to a two- to three-fold reduction  
342 in whole-cell  $\beta$ -galactosidase activity in cells expressing the *malF-lacZ102* fusion in the  
343 absence of DsbA. This finding is consistent with previous studies, which have implicated  
344 FkpA in the folding of exogenous proteins in the periplasm, and, like our findings with  
345 DegP and DsbA, it confirms that LacZ is fully translocated into the periplasm. Whether



346 the PPIase activity of FkpA contributes to LacZ folding remains unclear, although LacZ  
347 does contain proline residues. We note that FkpA has previously been shown to prevent  
348 protein aggregation in the periplasm independent of its PPIase function (40).

349         The fact that a periplasmic factor contributes to LacZ folding is not surprising  
350 given the obstacles the periplasm presents to folding. LacZ is much larger than most  
351 periplasmic proteins, and it must tetramerize to form active enzyme (41). In the  
352 cytoplasm folding is driven by energy-dependent folding factors like GroEL and DnaJ/K;  
353 however, there are no homologs of these generalized folding factors in the periplasm, nor  
354 are there nucleotide triphosphates in the periplasm to drive energy-dependent folding  
355 (42). As previously discussed, the periplasm is also an oxidizing environment, and this is  
356 true even in the absence of DsbA as evidenced by the fact that *dsbA* is not essential under  
357 aerobic growth conditions. Given that *dsbA* disruption only partially relieves the Mal<sup>S</sup>  
358 phenotype of the *H\*lamB-lacZ* and *malF-lacZ102* fusions, we think it likely that some  
359 significant fraction of translocated LacZ is still misfolding even in the absence of DsbA.  
360 LacZ must have at least two fates in the periplasm then, folded or misfolded, with FkpA  
361 and DsbA contributing respectively to these fates.

362         We believe that this newly-discovered periplasmic  $\beta$ -galactosidase activity will be  
363 extremely useful in designing screens for periplasmic folding factors. It is likely that  
364 additional factors contribute to LacZ folding, since the *malF-lacZ102* fusion still confers  
365  $\beta$ -galactosidase activity in the absence of FkpA. Screening for folding factors in an *fkpA*  
366 null background will help overcome the functional redundancy of periplasmic  
367 chaperones. Identifying such periplasmic folding factors and efficiently targeting

368 recombinant proteins to the periplasm are keys to the effective expression of exogenous  
369 proteins requiring disulfide bonds in *E. coli*.  
370

371

ACKNOWLEDGMENTS

372

This work was supported by National Institute of General Medical Sciences grant

373

GM34821 awarded to T.J.S. J.B. and D.B. were supported by National Institute of

374

General Medical Sciences grant GMO41883.

375

376

REFERENCES

- 377 1. **Silhavy TJ, Shuman H, Beckwith J, Schwartz M.** 1977. Use of gene fusions to  
378 study outer membrane protein localization in *Escherichia coli*. *Proc. Natl. Acad.*  
379 *Sci. U. S. A.* **74**:5411–5.
- 380 2. **Bassford PJ, Silhavy TJ.** 1979. Use of Gene Fusion to Study Secretion of  
381 Maltose-Binding Protein into *Escherichia coli* Periplasm.
- 382 3. **Van Stelten J, Silva F, Belin D, Silhavy TJ.** 2009. Effects of antibiotics and a  
383 proto-oncogene homolog on destruction of protein translocator SecY. *Science*  
384 **325**:753–6.
- 385 4. **Emr SD, Schwartz M, Silhavy TJ.** 1978. Mutations altering the cellular  
386 localization of the phage lambda receptor, an *Escherichia coli* outer membrane  
387 protein. *Proc. Natl. Acad. Sci. U. S. A.* **75**:5802–5806.
- 388 5. **Emr SD, Silhavy TJ.** 1980. Mutations affecting localization of an *Escherichia coli*  
389 outer membrane protein, the bacteriophage lambda receptor. *J. Mol. Biol.* **141**:63–  
390 90.
- 391 6. **Kumamoto CA, Beckwith J.** 1983. Mutations in a new gene, *secB*, cause  
392 defective protein localization in *Escherichia coli*. *J. Bacteriol.* **154**:253–60.
- 393 7. **Emr SD, Hanley-Way S, Silhavy TJ.** 1981. Suppressor mutations that restore  
394 export of a protein with a defective signal sequence. *Cell* **23**:79–88.
- 395 8. **Oliver DB, Beckwith J.** 1981. *E. coli* mutant pleiotropically defective in the  
396 export of secreted proteins. *Cell* **25**:765–72.
- 397 9. **Danese PN, Silhavy TJ.** 1998. Targeting and assembly of periplasmic and outer-  
398 membrane proteins in *Escherichia coli*. *Annu. Rev. Genet.* **32**:59–94.

- 399 10. **Newton WA, Beckwith JR, Zipser D, Brenner S.** 1965. Nonsense mutants and  
400 polarity in the Lac operon of Escherichia coli. *J. Mol. Biol.* **14**:290–296.
- 401 11. **Snyder WB, Silhavy TJ.** 1995. Beta-galactosidase is inactivated by  
402 intermolecular disulfide bonds and is toxic when secreted to the periplasm of  
403 Escherichia coli. *Microbiology* **177**:953–963.
- 404 12. **Bowers CW, Lau F, Silhavy TJ.** 2003. Secretion of LamB-LacZ by the Signal  
405 Recognition Particle Pathway of Escherichia coli. *J. Bacteriol.* **185**:5697–5705.
- 406 13. **Hall MN, Schwartz M, Silhavy TJ.** 1982. Sequence Information within the lamB  
407 Gene is Required for Proper Routing of the Bacteriophage Lambda Receptor  
408 Protein to the Outer Membrane of Escherichia coli K-12. *J. Mol. Biol.* **156**:93–  
409 112.
- 410 14. **Froshauer S, Green GN, Boyd D, McGovern K, Beckwith J.** 1988. Genetic  
411 analysis of the membrane insertion and topology of MalF, a cytoplasmic  
412 membrane protein of Escherichia coli. *J. Mol. Biol.* **200**:501–11.
- 413 15. **Bardwell JC, McGovern K, Beckwith J.** 1991. Identification of a protein  
414 required for disulfide bond formation in vivo. *Cell* **67**:581–9.
- 415 16. **Beckwith J.** 2013. Fifty years fused to lac. *Annu. Rev. Microbiol.* **67**:1–19.
- 416 17. **Silhavy TJ, Berman ML, Enquist LW.** 1984. *Experiments With Gene Fusions.*  
417 Cold Spring Harbor Laboratory.
- 418 18. **Datsenko KA, Wanner BL.** 2000. One-step inactivation of chromosomal genes in  
419 Escherichia coli K-12 using PCR products. *Proc. Natl. Acad. Sci. U. S. A.*  
420 **97**:6640–5.

- 421 19. **Hansson MD, Rzeznicka K, Rosenbäck M, Hansson M, Sirijovski N.** 2008.  
422 PCR-mediated deletion of plasmid DNA. *Anal. Biochem.* **375**:373–5.
- 423 20. **Miller JH.** 1972. Experiments in molecular genetics. Cold Spring Harbor  
424 Laboratory, Cold Spring Harbor, NY.
- 425 21. **Schäfer U, Beck K, Müller M.** 1999. Skp, a molecular chaperone of gram-  
426 negative bacteria, is required for the formation of soluble periplasmic  
427 intermediates of outer membrane proteins. *J. Biol. Chem.* **274**:24567–74.
- 428 22. **Heppel LA.** 1967. Selective Release of Enzymes from Bacteria. *Science*  
429 **156**:1451–1455.
- 430 23. **Wang R, Xiang S, Feng Y, Srinivas S, Zhang Y, Lin M, Wang S.** 2013.  
431 Engineering production of functional scFv antibody in *E. coli* by co-expressing the  
432 molecule chaperone Skp. *Front. Cell. Infect. Microbiol.* **3**:72.
- 433 24. **Sonoda H, Kumada Y, Katsuda T, Yamaji H.** 2011. Effects of cytoplasmic and  
434 periplasmic chaperones on secretory production of single-chain Fv antibody in  
435 *Escherichia coli*. *J. Biosci. Bioeng.* **111**:465–70.
- 436 25. **Gunnarsen KS, Kristinsson SG, Justesen S, Frigstad T, Buus S, Bogen B,  
437 Sandlie I, Løset GÅ.** 2013. Chaperone-assisted thermostability engineering of a  
438 soluble T cell receptor using phage display. *Sci. Rep.* **3**:1162.
- 439 26. **Levy R, Ahluwalia K, Bohmann DJ, Giang HM, Schwimmer LJ, Issafras H,  
440 Reddy NB, Chan C, Horwitz AH, Takeuchi T.** 2013. Enhancement of antibody  
441 fragment secretion into the *Escherichia coli* periplasm by co-expression with the  
442 peptidyl prolyl isomerase, FkpA, in the cytoplasm. *J. Immunol. Methods* **394**:10–  
443 21.

- 444 27. **O'Reilly AO, Cole AR, Lopes JLS, Lampert A, Wallace BA.** 2014. Chaperone-  
445 mediated native folding of a  $\beta$ -scorpion toxin in the periplasm of *Escherichia coli*.  
446 *Biochim. Biophys. Acta* **1840**:10–5.
- 447 28. **Bothmann H, Pluckthun A.** 2000. The periplasmic *Escherichia coli*  
448 peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of  
449 antibody fragments with and without cis-prolines. *J. Biol. Chem.* **275**:17100–5.
- 450 29. **Missiakas D, Betton J-M, Raina S.** 1996. New components of protein folding in  
451 extracytoplasmic compartments of *Escherichia coli* SurA, FkpA and Skp/OmpH.  
452 *Mol. Microbiol.* **21**:871–884.
- 453 30. **Danese PN, Silhavy TJ.** 1997. The sigma(E) and the Cpx signal transduction  
454 systems control the synthesis of periplasmic protein-folding enzymes in  
455 *Escherichia coli*. *Genes Dev.* **11**:1183–93.
- 456 31. **Snyder WB, Davis LJ, Danese PN, Cosma CL, Silhavy TJ.** 1995.  
457 Overproduction of NlpE, a new outer membrane lipoprotein, suppresses the  
458 toxicity of periplasmic LacZ by activation of the Cpx signal transduction pathway.  
459 *J. Bacteriol.* **177**:4216–23.
- 460 32. **Danese PN, Snyder WB, Cosma CL, Davis LJ, Silhavy TJ.** 1995. The Cpx two-  
461 component signal transduction pathway of *Escherichia coli* regulates transcription  
462 of the gene specifying the stress-inducible periplasmic protease, DegP. *Genes Dev.*  
463 **9**:387–98.
- 464 33. **Moreno F, Fowler A V, Hall M, Silhavy TJ, Zabin I, Schwartz M.** 1980. A  
465 signal sequence is not sufficient to lead beta-galactosidase out of the cytoplasm.  
466 *Nature* **286**:356–9.

- 467 34. **Benson SA, Silhavy TJ.** 1983. Information within the mature LamB protein  
468 necessary for localization to the outer membrane of E coli K12. *Cell* **32**:1325–35.
- 469 35. **Gouridis G, Karamanou S, Gelis I, Kalodimos CG, Economou A.** 2009. Signal  
470 peptides are allosteric activators of the protein translocase. *Nature* **462**:363–7.
- 471 36. **Justice SS, Hunstad DA, Harper JR, Duguay AR, Pinkner JS, Bann J,**  
472 **Frieden C, Silhavy TJ, Hultgren SJ.** 2005. Periplasmic peptidyl prolyl cis-trans  
473 isomerases are not essential for viability, but SurA is required for pilus biogenesis  
474 in Escherichia coli. *J. Bacteriol.* **187**:7680–6.
- 475 37. **Schwalm J, Mahoney TF, Soltes GR, Silhavy TJ.** 2013. Role for Skp in LptD  
476 assembly in Escherichia coli. *J. Bacteriol.* **195**:3734–42.
- 477 38. **Wu T, McCandlish AC, Gronenberg LS, Chng S-S, Silhavy TJ, Kahne D.**  
478 2006. Identification of a protein complex that assembles lipopolysaccharide in the  
479 outer membrane of Escherichia coli. *Proc. Natl. Acad. Sci. U. S. A.* **103**:11754–9.
- 480 39. **Chng S-S, Ruiz N, Chimalakonda G, Silhavy TJ, Kahne D.** 2010.  
481 Characterization of the two-protein complex in Escherichia coli responsible for  
482 lipopolysaccharide assembly at the outer membrane. *Proc Natl Acad Sci*  
483 **107**:5363–8.
- 484 40. **Arié JP, Sassoon N, Betton JM.** 2001. Chaperone function of FkpA, a heat shock  
485 prolyl isomerase, in the periplasm of Escherichia coli. *Mol. Microbiol.* **39**:199–  
486 210.
- 487 41. **Jacobson RH, Zhang XJ, DuBose RF, Matthews BW.** 1994. Three-dimensional  
488 structure of beta-galactosidase from E. coli. *Nature* **369**:761–6.
- 489 42. **Gething MJ, Sambrook J.** 1992. Protein folding in the cell. *Nature* **355**:33–45.



- 490 43. **Casadaban MJ.** 1976. Transposition and fusion of the lac genes to selected  
491 promoters in Escherichia coli using bacteriophage lambda and Mu. J. Mol. Biol.  
492 **104**:541–55.
- 493 44. **Ruiz N, Gronenberg LS, Kahne D, Silhavy TJ.** 2008. Identification of two  
494 inner-membrane proteins required for the transport of lipopolysaccharide to the  
495 outer membrane of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. **105**:5537–42.
- 496 45. **Cosma CL, Crotwell MD, Burrows SY, Silhavy TJ.** 1998. Folding-based  
497 suppression of extracytoplasmic toxicity conferred by processing-defective LamB.  
498 J. Bacteriol. **180**:3120–30.
- 499
- 500
- 501

502 **Table 1** Strains, plasmids, and phage

Strain, plasmid, or phage	Genotype or relevant description	Reference(s) or source(s)
NR754	MC4100 F <sup>-</sup> <i>araD</i> <sup>+</sup> Δ( <i>argF-lac</i> ) <i>U169 rpsL150 relA1 fibB5301 deoC1 ptsF25 thi</i>	(43, 44)
CWB299	MC4100 Φ( <i>H*lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)] <i>H*lamB</i>	(12)
JCM911	JCM913 pKD46	This study
JCM912	NR754 Φ( <i>lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study; (1)
JCM913	NR754 Φ( <i>lamBΔ60'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study; (5)
JCM914	NR754 Φ( <i>lamB-lacZX90</i> ) Hyb42-1 [λp1(209)]	This study; (11)
JCM932	NR754 Φ( <i>PlamB Δ230::Kan<sup>r</sup> lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)] pKD46	This study
JCM944	NR754 Φ( <i>H*lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD106	NR754 pNG102	This study
RSD107	NR754 Φ( <i>H*SS+90lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD108	NR754 Φ( <i>H*SS+49lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD109	NR754 Φ( <i>H*SS+43lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD110	NR754 Φ( <i>H*SS+27lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD111	NR754 Φ( <i>H*SS+5lamB'</i> - <i>lacZ</i> ) Hyb42-1 [λp1(209)]	This study
RSD112	JCM913 pDegP	This study
RSD113	JCM912 pDegP	This study
RSD114	JCM914 pDegP	This study
RSD115	JCM944 pDegP	This study
RSD116	RSD106 pDegP	This study
RSD117	JCM913 <i>dsbA::Kan<sup>r</sup></i>	This study
RSD118	JCM912 <i>dsbA::Kan<sup>r</sup></i>	This study
RSD119	JCM914 <i>dsbA::Kan<sup>r</sup></i>	This study
RSD120	JCM944 <i>dsbA::Kan<sup>r</sup></i>	This study
RSD121	RSD106 <i>dsbA::Kan<sup>r</sup></i>	This study
RSD122	JCM913 <i>lacY::Tn9</i>	This study
RSD123	JCM944 <i>lacY::Tn9</i>	This study
RSD124	RSD117 <i>lacY::Tn9</i>	This study
RSD125	RSD120 <i>lacY::Tn9</i>	This study
RSD126	RSD121 Δ <i>skp yafC::Tn10</i>	This study
RSD127	RSD121 Δ <i>fkpA::Cm<sup>r</sup></i>	This study
pNG102	Amp <sup>r</sup> LacZ <sup>-</sup> <i>PmalmaIE'</i> Φ( <i>malF-lacZ</i> ) Hyb102	(14)
pDegP	Cm <sup>r</sup> pACYC184:: <i>degP</i>	(45)
pKD4	Amp <sup>r</sup> Kan <sup>r</sup>	(18)
pKD46	Amp <sup>r</sup> <i>ParaB</i> λ-Red recombinase γ β <i>exo</i>	(18)
pCWB36	<i>H*lamB</i>	(12)
pRSD02	pBR322:: <i>H*lamB-lacZ'</i> Tet <sup>r</sup>	This study
λp1(209)	::(+Mu') <i>trp'BA'</i> – W209 <i>lac 'O Z U118Y A'</i>	(43)

503  
504

**Table 2** Inducer sensitivity profiles of fusion strains

Fusion	Zone of Inhibition (mm)		
	Wild Type <sup>a</sup>	pDegP <sup>b</sup>	<i>dsbA</i> ::Kan <sup>R</sup>
$\Delta 60$ <i>lamB-lacZ</i>	0	0	0
<i>lamB-lacZ42-1</i>	25	19	23
<i>lamB-lacZX90</i>	23	0	24
<i>H*</i> <i>lamB-lacZ</i>	11	0	4
<i>malF-lacZ102</i>	28	0	2

505

506 <sup>a</sup>The wild type heading indicates strains with fusions present in the NR754 background without  
507 plasmids or markers. See fusion strains JCM913, JCM912, JCM914, JCM944, and RSD06.

508 <sup>b</sup>The pDegP heading indicates fusion strains containing a high copy *degP* plasmid. See fusion  
509 strains are RSD112-116.

510 <sup>c</sup>The *dsbA*::Kan<sup>R</sup> heading refers to strains RSD117-121.

511

**Table 3** Inducer sensitivity of the *H\*lamB-lacZ* deletion series

Strain	Mature LamB sequence <sup>a</sup>	Zone of inhibition (mm)
JCM944	173	7
RSD107	90	7
RSD108	49	6
RSD109	43	7
RSD110	27	8
RSD111	5	7

512

513 <sup>a</sup>The number of mature LamB residues included in addition to the *H\**LamB signal sequence.

514

515 **Figure 1.** Construction of JCM944. (A,B,D,F) Note that the  $\lambda$  insertion is  $\lambda p1(209)$ . (A)  
516 CWB299. CWB299 is an *H\*lamB* merodiploid, containing a copy of *H\*lamB* in addition to the  
517 *H\*lamB-lacZ* fusion. (B) JCM911. Construction of a haploid *H\*lamB-lacZ* strain began with a  
518 strain containing the  $\Delta 60lamB-lacZ$  fusion and pKD46. JCM911 was recombineered with the  
519 linear DNA fragment depicted in (C). The fragment was obtained by PCR amplification of the  
520 Kan<sup>R</sup> cassette present on pKD4 with primers having 5' homology to *malK* and *lamB*. The primers  
521 were designed to generate a Kan<sup>R</sup> insertion-deletion removing 27 nucleotides upstream of the  
522 *lamB* ORF and 200 nucleotides downstream ( $\Delta 230::Kan^R$ ). The result of the recombineering  
523 reaction is JCM932 depicted in (D). The  $\Delta 230::Kan^R$  insertion-deletion is polar on the *lac* operon,  
524 preventing expression of *lacY*. As a result JCM932 cannot grow on minimal melibiose at 42°C.  
525 JCM932 was then recombineered with the linear DNA fragment depicted in (E). The fragment  
526 was obtained by PCR amplification of *malK* and *H\*lamB* from pCWB36. Recombinants that  
527 replaced the  $\Delta 230::Kan^R$  insertion-deletion and restored *lacY* expression were selected on  
528 minimal melibiose at 42°C and subsequently screened for Kan<sup>S</sup>. (F) JCM944 was identified as a  
529 Mel<sup>+</sup> Kan<sup>S</sup> recombinant.  
530

531 **Figure 2** Effect of DsbA on whole cell  $\beta$ -galactosidase activity. Overnight cultures were washed  
532 and subcultured 1:50 into liquid LB cultures. Cultures were incubated with aeration at 37°C for 2-  
533 3 hours until reaching mid-log phase.  $\beta$ -galactosidase activity was determined from  $V_{max}$  of whole  
534 cell lysates in a kinetic Miller assay.  $\Delta 60$  indicates strains JCM913 ( $dsbA^+$ ) and RSD117  
535 ( $dsbA::Kan^R$ ). 42-1 indicates strains JCM912 ( $dsbA^+$ ) and RSD118 ( $dsbA::Kan^R$ ). H\* indicates  
536 strains JCM944 ( $dsbA^+$ ) and RSD120 ( $dsbA::Kan^R$ ), and 102 indicates strains RSD06 ( $dsbA^+$ )  
537 and RSD121 ( $dsbA::Kan^R$ ). Error bars show standard deviation calculated from three  
538 independent biological replicates.  
539

540 **Figure 3** Effect of DsbA on periplasmic  $\beta$ -galactosidase activity. (A,B) Error bars show standard  
541 deviations calculated from three independent biological replicates. (A) Bypassing *lacY*.  
542 Overnight cultures were washed and subcultured in minimal media containing glycerol or lactose  
543 as the sole carbon source.  $\Delta 60$  indicates strains containing the  $\Delta 60$ *lamB-lacZ* fusion in a wild  
544 type background (JCM913, white), a *lacY::Tn9* background (RSD122, grey), or a *lacY::Tn9*  
545 *dsbA::Kan<sup>R</sup>* background (RSD124, black). H\* indicates strains containing the *H\*lamB-lacZ* fusion  
546 in a wild type background (JCM944, white), a *lacY::Tn9* background (RSD123, grey), or a  
547 *lacY::Tn9 dsbA::Kan<sup>R</sup>* background (RSD125, black). 102 indicates strains containing the *malF-*  
548 *lacZ102* fusion in a wild type background without *lacY* (RSD06, grey) or a *dsbA::Kan<sup>R</sup>*  
549 background (RSD121, black). (B,C) Overnight cultures were washed and subcultured 1:50 into  
550 liquid LB cultures. Cultures were incubated with aeration at 37°C for 2-3 hours until reaching mid-  
551 log phase.  $\Delta 60$  refers to RSD117 (*dsbA::Kan<sup>R</sup>*), and H\* refers to RSD120 (*dsbA::Kan<sup>R</sup>*). (B)  
552 Releasing soluble periplasmic  $\beta$ -galactosidase activity.  $\beta$ -galactosidase activity was determined  
553 from  $V_{max}$  of whole-cell lysates or filtered spheroplast supernatants in a kinetic Miller assay.  
554 Periplasmic  $\beta$ -galactosidase activity is reported as a fraction of whole-cell  $\beta$ -galactosidase  
555 activity. (C) Spheroplasting lysis control. Whole-cell lysates or filtered spheroplast supernatants  
556 were subject to SDS-PAGE and Western blotting. MBP is used as a marker for soluble  
557 periplasmic proteins. CpxR is used as a marker of soluble cytoplasmic proteins.  
558

559 **Figure 4** Effect of periplasmic chaperones on periplasmic  $\beta$ -galactosidase activity. Overnight  
560 cultures were washed and subcultured 1:50 into liquid LB cultures. Cultures were incubated with  
561 aeration at 30°C for 2-3 hours until reaching mid-log phase.  $\beta$ -galactosidase activity was  
562 determined from  $V_{max}$  of whole cell lysates in a kinetic Miller assay.  $\beta$ -galactosidase activity is  
563 normalized to RSD121. Error bars show standard deviation calculated from three independent  
564 biological replicates. 102 indicates RSD121.  $\Delta skp$  indicates RSD126.  $fkpA::Cm^R$  indicates  
565 RSD127.









